Dr Reddys Laboratories Ltd (500124)
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Dr. Reddy's entered an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India for Qdenga®, India's first CDSCO approved dengue vaccine, in the private market. The vaccine is expected to be available in H1 2027. Dr. Reddy's will handle promotion and distribution, while Takeda retains public market commercialization and manufacturing rights. The collaboration supports dengue prevention amid rising cases in India and aligns with Dr. Reddy's vaccine strategy.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 500124 — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add 500124 to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Dr Reddys Laboratories Ltd
Important.
The summary above is generated automatically from Dr Reddys Laboratories Ltd's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.